@prefix prodottidellaricerca: . @prefix istituto: . @prefix prodotto: . istituto:CDS035 prodottidellaricerca:prodotto prodotto:ID203362 . @prefix pubblicazioni: . @prefix unitaDiPersonaleInterno: . unitaDiPersonaleInterno:MATRICOLA10391 pubblicazioni:autoreCNRDi prodotto:ID203362 . unitaDiPersonaleInterno:MATRICOLA11049 pubblicazioni:autoreCNRDi prodotto:ID203362 . unitaDiPersonaleInterno:MATRICOLA10800 pubblicazioni:autoreCNRDi prodotto:ID203362 . @prefix rdf: . @prefix retescientifica: . prodotto:ID203362 rdf:type retescientifica:ProdottoDellaRicerca , prodotto:TIPO1305 . @prefix rdfs: . prodotto:ID203362 rdfs:label "Efficacy and safety of niacin/laropiprant therapy in familial hypercholesterolemic patients with coronary artery disease (Abstract/Comunicazione in atti di convegno)"@en . @prefix xsd: . prodotto:ID203362 pubblicazioni:anno "2011-01-01T00:00:00+01:00"^^xsd:gYear . @prefix skos: . prodotto:ID203362 skos:altLabel "
F. Sbrana, M. Puntoni, F. Bigazzi, S. Vicari, E. Grisanti, A. Ragusa, M. Pianelli, R. Luciani, T. Sampietro (2011)
Efficacy and safety of niacin/laropiprant therapy in familial hypercholesterolemic patients with coronary artery disease
in 25. congresso nazionale SISA, Roma, 30 novembre - 3 dicembre 2011
"^^rdf:HTML ; pubblicazioni:autori "F. Sbrana, M. Puntoni, F. Bigazzi, S. Vicari, E. Grisanti, A. Ragusa, M. Pianelli, R. Luciani, T. Sampietro"^^xsd:string ; pubblicazioni:paginaInizio "95"^^xsd:string ; pubblicazioni:paginaFine "96"^^xsd:string ; pubblicazioni:altreInformazioni "ID_PUMA: cnr.ifc/2011-B6-012"^^xsd:string ; pubblicazioni:url "http://www.sisa.it/index.php?class=Comp&className=Content&op=Show¶m=cid,367,preview,0"^^xsd:string ; pubblicazioni:numeroVolume "2"^^xsd:string . @prefix ns10: . prodotto:ID203362 pubblicazioni:rivista ns10:ID544974 ; pubblicazioni:numeroFascicolo "3"^^xsd:string ; skos:note "Abstract"^^xsd:string ; pubblicazioni:affiliazioni "Fondazione CNR, Regione Toscana \\\"Gabriele Monasterio\\\", Pisa, Italy ; CNR Institute of Clinical Physiology of Pisa, Italy"^^xsd:string ; pubblicazioni:titolo "Efficacy and safety of niacin/laropiprant therapy in familial hypercholesterolemic patients with coronary artery disease"^^xsd:string ; prodottidellaricerca:abstract "Background: Cardiovascular disease is the principal cause of premature mortality and morbidity in Europe. Patients with familial hypercholesterolemia are at particularly increased risk and, despite lipid-lowering therapy, continue to experience cardiovascular events. Currently, for these patients a new treatment option is represented by extended-release niacin/laropiprant (ERN/LRPN). Material and Methods: We followed-up for 16 weeks a group of 23 familial hypercholesterolemic patients (mean age 61\u00B17 years, 74% male) with chronic coronary artery disease and ERN/LRPN added on top of maximally tolerated lipid-lowering therapy. ERN/LRPN was administered at the dose of 1 gr/day for the first 4 weeks and then at 2 gr/day for the remaining period. Clinical examination and blood sampling (including lipid profile, renal and hepatic function) were performed at baseline, after 4 weeks, at the end of follow-up, and in the case of eventual clinical manifestations. Results: During follow-up, 14 patients discontinued therapy due to side effects (headache, asthenia, and gastrointestinal disorders in 4 patients, muscle aches and CK increase in 3 patients, eruptive skin rash in 2 patients, onset of diabetes mellitus in 2 patients, dizziness associated with inability to drive in 1 patient, acute hepatitis in 1 patient and palpitations in 1 patient) and 2 patients voluntarily interrupted the therapy. In the remaining 7 patients, an improvement in lipid profile was observed (total cholesterol -14%, HDL cholesterol +7%, LDL cholesterol -16%, Triglycerides -53%, Apolipoprotein A1 +8%, Apolipoprotein B -21%, Apolipoprotein E -31%) in the absence of substantial changes in other laboratory analyses (with the exception of a non-significant increase in uric acid). Intolerable skin flushing was not observed in any patient. In addition, among patients who did report flushing, a reduction in the incidence of the episodes was observed after the first month of therapy."@en ; prodottidellaricerca:prodottoDi istituto:CDS035 . @prefix modulo: . prodotto:ID203362 prodottidellaricerca:prodottoDi modulo:ID6811 ; pubblicazioni:autoreCNR unitaDiPersonaleInterno:MATRICOLA11049 , unitaDiPersonaleInterno:MATRICOLA10800 , unitaDiPersonaleInterno:MATRICOLA10391 . ns10:ID544974 pubblicazioni:rivistaDi prodotto:ID203362 . modulo:ID6811 prodottidellaricerca:prodotto prodotto:ID203362 .